- Your physician may carry out a procedure known as plasma exchange. The purpose of this is to remove plasma from your body that contains the faulty proteins and replace it with fresh plasma containing non – faulty proteins.
- This procedure normally lasts a few hours and you will need a line to be inserted into one of your larger blood vessels for it to be carried out.
Eculizumab and Ravulizumab
- Eculizumab (Soliris©) and Ravulizumab are medications currently licensed for use in aHUS.
- They work by blocking the action of complement and therefore preventing it from damaging the body’s own cells.
- Eculizumab and Ravulizumab are given as an infusion that usually lasts up to an hour for most patients, but can be longer if the infusion is for a child.
- For eculizumab, after the first doses have been given, the regular long-term dose interval is every two weeks in patients over 10kg and every three weeks for children under 10kg
- Historically Eculizumab was given for the remainder of your life but this may change in the future depending on the results of a clinical trial currently running to if it is safe to stop Eculizumab / Ravulizumab infusions, and what monitoring should be done when the infusions stop.